Share on StockTwits

Equities research analysts at Brean Capital initiated coverage on shares of Endocyte (NASDAQ:ECYT) in a research note issued to investors on Tuesday. The firm set a “buy” rating and a $22.00 price target on the stock. Brean Capital’s price target suggests a potential upside of 231.83% from the company’s current price.

Shares of Endocyte (NASDAQ:ECYT) traded down 5.13% during mid-day trading on Tuesday, hitting $6.29. The stock had a trading volume of 758,864 shares. Endocyte has a one year low of $6.01 and a one year high of $33.70. The stock’s 50-day moving average is $6.57 and its 200-day moving average is $12.55. The company’s market cap is $261.1 million.

Endocyte (NASDAQ:ECYT) last released its earnings data on Friday, May 2nd. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.14) by $0.05. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.07 million. Analysts expect that Endocyte will post $-0.18 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Monday. They now have a $7.90 price target on the stock. Separately, analysts at Chardan Capital cut their price target on shares of Endocyte from $26.00 to $15.00 in a research note on Wednesday, June 18th. They now have a “buy” rating on the stock. Finally, analysts at RBC Capital cut their price target on shares of Endocyte from $20.00 to $15.00 in a research note on Wednesday, June 18th. They now have an “outperform” rating on the stock. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.49.

Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.